OpenURL Connection Search

Select item for more details and to access through your institution.

PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 560, doi. 10.1002/hon.7_2632
By:
- Jaeger, U.;
- McGuirk, J.;
- Worel, N.;
- Riedell, P.;
- Fleury, I.;
- Borchmann, P.;
- Forcina, A.;
- Chu, J.;
- Leung, M.;
- Pacaud, L.;
- Waller, E.
Publication type:
Article
ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 559, doi. 10.1002/hon.6_2632
By:
- Dickinson, M.;
- Popplewell, L.;
- Kolstad, A.;
- Ho, P.J.;
- Teshima, T.;
- Dreyling, M.;
- Schuster, S.;
- Thieblemont, C.;
- Ghosh, M.;
- Riedell, P.;
- Yateman, N.;
- Lehnhoff, K.;
- Lawniczek, T.;
- Pacaud, L.;
- Fowler, N.
Publication type:
Article
BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 558, doi. 10.1002/hon.5_2632
By:
- Minard‐Colin, V.;
- Burkhardt, B.;
- Maude, S.;
- Phillips, C.;
- Diaz de Heredia Rubio, C.;
- Laetsch, T.W.;
- Curran, K.;
- Newsome, S.;
- Murray, N.;
- Pacaud, L.;
- Buechner, J.
Publication type:
Article
PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 560, doi. 10.1002/hon.7_2632
By:
- Jaeger, U.;
- McGuirk, J.;
- Worel, N.;
- Riedell, P.;
- Fleury, I.;
- Borchmann, P.;
- Forcina, A.;
- Chu, J.;
- Leung, M.;
- Pacaud, L.;
- Waller, E.
Publication type:
Article
ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 559, doi. 10.1002/hon.6_2632
By:
- Dickinson, M.;
- Popplewell, L.;
- Kolstad, A.;
- Ho, P.J.;
- Teshima, T.;
- Dreyling, M.;
- Schuster, S.;
- Thieblemont, C.;
- Ghosh, M.;
- Riedell, P.;
- Yateman, N.;
- Lehnhoff, K.;
- Lawniczek, T.;
- Pacaud, L.;
- Fowler, N.
Publication type:
Article
BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 558, doi. 10.1002/hon.5_2632
By:
- Minard‐Colin, V.;
- Burkhardt, B.;
- Maude, S.;
- Phillips, C.;
- Diaz de Heredia Rubio, C.;
- Laetsch, T.W.;
- Curran, K.;
- Newsome, S.;
- Murray, N.;
- Pacaud, L.;
- Buechner, J.
Publication type:
Article
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS.
Published in:
Hematological Oncology, 2017, v. 35, p. 27, doi. 10.1002/hon.2437_6
By:
- Schuster, S.J.;
- Bishop, M.R.;
- Tam, C.;
- Waller, E.K.;
- Borchmann, P.;
- Mcguirk, J.;
- Jäger, U.;
- Jaglowski, S.;
- Andreadis, C.;
- Westin, J.;
- Fleury, I.;
- Bachanova, V.;
- Foley, S.R.;
- Ho, P.J.;
- Mielke, S.;
- Holte, H.;
- Anak, O.;
- Pacaud, L.;
- Awasthi, R.;
- Tai, F.
Publication type:
Article

Found: 7

PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.

BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA.

PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.

ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA.

BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA.

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS.